Identification of Residues in CD6 Which Are Critical for Ligand Binding-Reference-Cited by-同舟云学术

Identification of Residues in CD6 Which Are Critical for Ligand Binding

Published:1997-03-01 Issue:9 Volume:36 Page:2637-2641
ISSN:0006-2960
Container-title:Biochemistry
language:en
Short-container-title:Biochemistry

Author:

Bodian Dale L.¹,Skonier John E.¹,Bowen Michael A.¹,Neubauer Michael¹,Siadak Anthony W.¹,Aruffo Alejandro¹,Bajorath Jürgen¹

Affiliation:

1. Bristol-Myers Squibb Pharmaceutical Research Institute, 3005 First Avenue, Seattle, Washington 98121, and Department of Biological Structure, University of Washington, Seattle, Washington 98195

Publisher

American Chemical Society (ACS)

Subject

Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/bi962560%2B

Reference20 articles.

1. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins.

2. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.

3. The Amino-terminal Immunoglobulin-like Domain of Activated Leukocyte Cell Adhesion Molecule Binds Specifically to the Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 with a 1:1 Stoichiometry

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dual role of CD6 as a therapeutic target in cancer and autoimmune disease;Frontiers in Medicine;2022-10-05

2. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases;Immunotherapy;2021-03

3. Targeting the lysyl oxidases in tumour desmoplasia;Biochemical Society Transactions;2019-11-22

4. Modulation of CD4 T cell function via CD6-targeting;EBioMedicine;2019-09

5. Clinical and experimental evidence for targeting CD6 in immune-based disorders;Autoimmunity Reviews;2018-05